PRKN and Alzheimer disease: To determine the effects of Bosutinib on Abl inhibition and parkin levels in vivo, we treated (5 mg/kg IP injection) for 3 weeks 8–12 months old AD transgenic mice, which express neuronally derived human APP gene, 770 isoform, containing the Swedish K670N/M671L, Dutch E693Q and Iowa D694N mutations (Tg-APP) under the control of the mouse thymus cell antigen 1, theta, Thy1, promoter (Davis et al, 2004).